Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561950 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT01561950: Clinical Trial Phase 1 study, sponsored by Novo Nordisk A/S.
NCT01561950 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 91 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01561950, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with clopidogrel (Plavix®).
Interventions
- DRUG placebo
- DRUG clopidogrel
- DRUG eptacog alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Why NCT01561950 stopped before completion
NCT01561950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01561950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01561950 about?
NCT01561950 is a clinical study titled "Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding". This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with clopidogrel (Plavix®).
What is the current status of trial NCT01561950?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2008-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT01561950?
The interventions under investigation include: placebo (DRUG), clopidogrel (DRUG), eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT01561950?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01561950's enrollment target sits among peer trials
91 626th of 2000 higher than 1,373 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia